Celltrion under scrutiny in insider trading probe

It's another insider trading probe for the pharma business. South Korean regulators are investigating allegations that the CEO of Celltrion, the biosimilars developer, profited off insider knowledge. The company says it hasn't engaged in anything like insider trading but confirmed the government investigation. Report